The unexpected weight gain in your 40s

When you bring this to a primary care provider, the explanation you most often receive is: metabolism slows with age. This is technically accurate. It is not useful as advice because it explains nothing about why it's happening now, what specifically has changed, and what could actually be done about it. It also implies a passive inevitability that isn't entirely warranted — the metabolic shift of midlife is real, but it's driven by specific, identifiable mechanisms, and those mechanisms are not all equally beyond influence.

The first mechanism is the one that gets the least plain-language explanation: the decline in sex hormones reshapes fat distribution in ways that are independent of caloric intake. In women, estrogen promotes fat storage in the hips and thighs — subcutaneous adipose tissue — rather than the visceral depot surrounding the abdominal organs. As estrogen declines in perimenopause, this hormonal directional signal weakens. The body doesn't store less fat; it stores it differently. The visceral depot, which is metabolically active in ways that subcutaneous fat is not, expands. This is the belly that feels different from the belly you had at thirty-two, because it is biologically different — it's metabolically distinct tissue, associated with different inflammatory profiles and different health implications than subcutaneous fat. The shift in fat distribution is not a story about eating too much. It's a story about where an unchanged level of excess energy is now being routed.

In men, the testosterone decline that proceeds gradually through the forties affects fat distribution through related but distinct mechanisms. Testosterone suppresses visceral fat accumulation and promotes lean mass retention. As testosterone declines, both effects weaken — visceral fat accumulates more readily, and lean mass, which has a higher resting metabolic rate than fat tissue, becomes harder to maintain. The result is a double shift: body composition moves toward more fat and less muscle even at the same body weight, which means resting metabolic rate declines in a self-reinforcing way. The same caloric intake that previously maintained a composition with more muscle now produces slow, steady fat accumulation.

The growth hormone axis is the second mechanism and the one that most people haven't heard explained clearly. GH secretion declines dramatically through adulthood — by the time most people are in their forties, they're secreting a fraction of the GH they produced in their twenties. This matters for body composition because GH supports lean mass retention, promotes lipolysis in adipose tissue, and indirectly supports insulin sensitivity through IGF-1 signaling. The decline in GH-axis activity doesn't produce dramatic symptoms on its own — it's subtle enough that most people don't notice it as an isolated event. But it shifts the metabolic baseline in the direction of less lean mass, more fat tissue, and somewhat reduced metabolic rate. When this decline runs in parallel with declining sex hormones and modestly worsening insulin sensitivity, the cumulative effect is the weight gain you can't explain by looking at your diet.

Insulin sensitivity changes through midlife in ways that are distinct from diabetes but that operate along the same biological pathways. Skeletal muscle — the primary tissue responsible for glucose disposal after meals — becomes modestly less insulin-sensitive with age, particularly in the context of declining lean mass and declining GH-axis activity. The result is that post-meal glucose tends to be handled somewhat less efficiently, with higher peak glucose excursions and slower disposal. This accelerates glycation and promotes fat storage, particularly in the visceral depot. The fasting insulin level that was completely normal at thirty-five may now be creeping upward even if fasting glucose remains in the normal range — a pattern that can precede overt insulin resistance by years and that standard screening often misses.

Sleep architecture changes in a direction that's relevant to body weight in ways that most discussions of "sleep and weight" don't adequately specify. Slow-wave sleep — the deep non-REM stages — is when GH is most actively secreted. It's also when leptin is most active and ghrelin is suppressed, maintaining the hormonal environment that signals satiety. As slow-wave sleep compresses with age (a well-documented physiological change that begins in the thirties), GH secretion is curtailed, and the overnight hormonal environment shifts toward patterns associated with increased appetite and reduced satiety the following day. If you're also sleeping six and a half hours rather than eight because life is full, you're compounding age-related slow-wave compression with voluntary sleep restriction, and the effect on appetite regulation and body composition is cumulative.

Cortisol patterns shift in midlife in ways that are relevant and often overlooked. The morning cortisol awakening response — which should be sharp and rapid in healthy adults — sometimes becomes blunted or prolonged in people with chronic high stress loads. This matters because cortisol affects both fat distribution (elevated cortisol chronically promotes visceral fat accumulation) and glucose metabolism (cortisol is a glucocorticoid, promoting gluconeogenesis and insulin resistance). The midlife body under sustained work and life stress is carrying a higher cortisol burden than the body in its early thirties, and that burden contributes directly to the composition shift.

Thyroid function is worth evaluating specifically and is one of the places conventional medicine sometimes undershoots. Thyroid disease is screened for with TSH, but TSH alone misses the picture for people with subclinical or early thyroid dysfunction. Free T4 and particularly free T3 provide better information about the thyroid hormones that actually regulate metabolic rate at the cellular level. Subclinical hypothyroidism — a mildly elevated TSH with normal free T4 — is common in midlife and contributes to weight gain, fatigue, and cold intolerance that can look indistinguishable from generic midlife metabolic slowdown. Hashimoto's thyroiditis, which is autoimmune and sometimes presents with a normal standard thyroid panel, can produce significant metabolic effects that standard screening doesn't capture.

The workup worth having in this context goes beyond the standard annual physical panel. Thyroid with free T3 and T4. Sex hormones — estradiol, testosterone, and critically SHBG (sex hormone-binding globulin), which determines how much of measured testosterone is actually bioavailable. Fasting insulin alongside glucose, allowing HOMA-IR calculation as a measure of insulin resistance that is far more sensitive than glucose or HbA1c alone in the early stages. IGF-1 as a proxy for GH-axis activity. DHEA-S. These are not exotic tests — they're available through standard labs — but they're not part of the default screening panel, and the composite picture they provide is substantially more informative than glucose and cholesterol alone.

Where peptide approaches enter the conversation depends on the workup. For people whose evaluation identifies significant GH-axis decline as a contributor, GH secretagogues — Sermorelin, Ipamorelin, CJC-1295, or Tesamorelin — have been researched for their effects on body composition, with Tesamorelin specifically having FDA approval for visceral adiposity in HIV lipodystrophy and meaningful off-label study in other visceral fat contexts. Tesamorelin in clinical trials has demonstrated statistically significant reduction in visceral adipose tissue, with effects distinct from caloric restriction and mediated through GH-axis stimulation. This is not a weight loss drug in the GLP-1 sense — it specifically targets the visceral depot and lean mass preservation rather than appetite and total weight. For the midlife body composition shift that involves a meaningful GH-axis contribution, this specificity may be relevant.

GLP-1 receptor agonists at therapeutic doses have been studied extensively for weight management and operate through appetite regulation and insulin sensitization. Microdose GLP-1 — lower doses than the weight loss indications — has been researched for insulin sensitivity and craving reduction in contexts where dramatic weight loss is not the goal, and for people whose evaluation reveals early insulin sensitivity decline as a primary driver, this may be worth a conversation with a prescribing provider.

Resistance training is not optional in this context. It is arguably the most potent available tool for preserving lean mass, improving insulin sensitivity, and partially counteracting the GH-axis decline through the exercise-stimulated GH pulse response. Protein adequacy — ensuring sufficient dietary protein to support lean mass maintenance, which most people in their forties underestimate — is a necessary substrate for any body composition approach to work. Sleep addressed seriously, not aspirationally.

The weight gain that doesn't make sense when you look at your diet makes complete sense when you look at the hormonal and metabolic environment the body is operating in. Nothing changed — and that's precisely why the outputs changed. The same inputs are now running through a different system, one in which the signals that historically promoted lean mass and regulated fat distribution have quietly shifted. Understanding which signals specifically is the first step toward addressing the right mechanisms rather than simply eating less of a diet that wasn't the problem.